News
Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study
A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk’s Wegovy. The study — published May 11 in the New England Journal of Medicine — followed 751 people across the U.
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.
Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.
Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...
The Lilly announcement will extend an agreement aimed at accelerating medicine development and bolstering the ...
A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...
Eli Lilly and Company and Purdue University are keeping their partnership alive beyond it’s previously expected years. In an ...
Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs ...
Eli Lilly and Purdue University expand their partnership with a $250 million investment to advance pharmaceutical innovation ...
Eli Lilly CEO Dave Ricks urged the Trump administration to move fast on foreign trade deals and warned of the harmful effects retaliatory tariffs could have on American exporters like Eli Lilly.
The new research and development site will combine research, process development and clinical trial manufacturing ...
Amazon.com, Nvidia, Tesla, and the rest of the Magnificent Seven stocks jump as the U.S. and China reach an agreement to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback